The Clinical Effecacy Of Feitai Capsule In The Treatment Of Advanced Non-small Cell Lung Cancer And Its Impact On Signal Transduction Pathway Of NF-κB

Objective:To investigate the relationship between the index change of NF-KB,pre-imflammatory factors(TNF-α,IL-1,IL-6) and the clinical efficacy of FeiTai capsule in the treatment of advanced non-small cell lung cancer(NSCLC),and to explore the impact of the drug on signal transduction pathway of NF-κB.Method:Select 60 patients of NSCLC who were confirmed by pathology,from February 2008 to November 2008,randomly divided into 2 groups:A group of 30 cases for the experimental group;orally 4 capsules every time,3 times daily for 4 weeks;30 cases as the control group were not administered by any anti-cancer,anti-inflammatory drugs.Observe the clinical efficacy,life quality,implication of tumor,test the content of NF-κBp65,IL-1β,IL-6, TNF-αin peripheral blood with enzyme-linked immunosorbent assay and analyze their interrelation.Result:1 Clinical Efficacy:(1) Symptoms Improvment:the experimental group:8 cases with excellent efficacy(26.7%).14 cases with therapeutic efficacy(46.7%),the total effective rate was 73.3%;the control group:4 cases with excellent efficacy(13.3%),8 cases with therapeutic efficacy(26.7%),the total effective rate was 40.0%,the difference was significant(P=0.01).(2) The improvd condition of life quality:After 4 weeks KPS score (Karnovfsky performance status,KPS) of the experimental group was improved clearly(P＜0.01),total effective rate was 66.7%;while improvement was not so obvious in the control group(P＞0.05),the total effective rate was 33.3%,the differences between two groups were significant(P=0.025).(3) Tumor's index:tumor volume change:a stable tumor rate [CR+PR+SD/N]:the experimental group 83.3%(25/30),the control group 73.3%(22/30), there was no significant difference between two groups(P=0.274).Significant change in two groups of CEA,CA-125 was not observed after 4 weeks(P＜0.05).(4) The detect of imflmmation-related index:there was no obvious change in the count of leucocyte,granulocyte, blood sendimentation after 4 weeks.2 Laboratory testing of pre-imflammatary factors and NF-κBp65:the IL-1β,IL-6,TNF-α,NF-κBp65 in cell nucleus of peripheral blood significantly declined in the experimental group after treatment,(P＜0.05),while there was significant difference between two groups(P＜0.05).3 There was significant interrelation between the difference of 4 indexs(IL-1β,IL-6,TNF-α,NF-κBp65) before and after the treatment and improvement of the clinical effecacy and life quality by the interrelated analysis.Conclusion:1 FeiTai Capsule could significantly improve the clinical symptoms,quality of life in advanced NSCLC patients.2 FeiTai Capsule may improve the clinical efficacy through interfering the activation of signal transduction pathway of NF-κB and reduction of the release of pre-imflammatory factors.